Cancer nanotechnology: current status and perspectives
JA Kemp, YJ Kwon - Nano convergence, 2021 - Springer
Modern medicine has been waging a war on cancer for nearly a century with no tangible
end in sight. Cancer treatments have significantly progressed, but the need to increase …
end in sight. Cancer treatments have significantly progressed, but the need to increase …
Pancreatic cancer: a review
W Park, A Chawla, EM O'Reilly - Jama, 2021 - jamanetwork.com
Importance Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer,
with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of …
with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of …
[HTML][HTML] Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis
PURPOSE To analyze the prevalence of homologous recombination deficiency (HRD) in
patients with pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS We …
patients with pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS We …
[HTML][HTML] Therapeutic implications of germline testing in patients with advanced cancers
ZK Stadler, A Maio, D Chakravarty… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Tumor mutational profiling is increasingly performed in patients with advanced
cancer. We determined the extent to which germline mutation profiling guides therapy …
cancer. We determined the extent to which germline mutation profiling guides therapy …
Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions
Simple Summary Tumor mutational burden (TMB) represents the number of mutations per
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …
Therapeutic developments in pancreatic cancer
ZI Hu, EM O'Reilly - Nature Reviews Gastroenterology & Hepatology, 2023 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …
lethal human malignancies. Much is known regarding the biology and pathophysiology of …
[HTML][HTML] Targeting DNA damage response and replication stress in pancreatic cancer
SB Dreyer, R Upstill-Goddard, V Paulus-Hock, C Paris… - Gastroenterology, 2021 - Elsevier
Background and aims Continuing recalcitrance to therapy cements pancreatic cancer (PC)
as the most lethal malignancy, which is set to become the second leading cause of cancer …
as the most lethal malignancy, which is set to become the second leading cause of cancer …
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
X Zhang, T Mao, B Zhang, H Xu, J Cui, F Jiao… - …, 2022 - thelancet.com
Background Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with an
extremely poor prognosis. Effective targets for anticancer therapy confirmed in PDAC are …
extremely poor prognosis. Effective targets for anticancer therapy confirmed in PDAC are …
Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Abstract Purpose: Approximately 8% to 10% of pancreatic ductal adenocarcinomas (PDAC)
do not harbor mutations in KRAS. Understanding the unique molecular and clinical features …
do not harbor mutations in KRAS. Understanding the unique molecular and clinical features …
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
ES Tsang, V Csizmok, LM Williamson… - NPJ Precision …, 2023 - nature.com
There is emerging evidence about the predictive role of homologous recombination
deficiency (HRD), but this is less defined in gastrointestinal (GI) and thoracic malignancies …
deficiency (HRD), but this is less defined in gastrointestinal (GI) and thoracic malignancies …